Canagliflozin primes antitumor immunity by triggering PD-L1 degradation in endocytic recycling

Understanding the regulatory mechanisms of PD-L1 expression in tumors provides key clues for improving immune checkpoint blockade efficacy or developing novel oncoimmunotherapy. Here, we showed that the FDA-approved sodium-glucose cotransporter-2 (SGLT2) inhibitor canagliflozin dramatically suppress...

Descripción completa

Detalles Bibliográficos
Autores principales: Ding, Ling, Chen, Xi, Zhang, Wenxin, Dai, Xiaoyang, Guo, Hongjie, Pan, Xiaohui, Xu, Yanjun, Feng, Jianguo, Yuan, Meng, Gao, Xiaomeng, Wang, Jian, Xu, Xiaqing, Li, Sicheng, Wu, Honghai, Cao, Ji, He, Qiaojun, Yang, Bo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9797339/
https://www.ncbi.nlm.nih.gov/pubmed/36594471
http://dx.doi.org/10.1172/JCI154754

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9797339/
https://www.ncbi.nlm.nih.gov/pubmed/36594471
http://dx.doi.org/10.1172/JCI154754

Ejemplares similares